Advances in lentiviral vectors: a patent review.
Lentiviral vectors are at the forefront of gene delivery systems for research and clinical applications. These vectors have the ability to efficiently transduce nondividing and dividing cells, to insert large genetic segment in the host chromatin, and to sustain stable long-term transgene expression. Most of lentiviral vectors systems in use are derived from HIV-1. Numerous modifications in the basic HIV structure have been made to ensure safety and to promote efficiency to vectors. Lentiviral vectors can be pseudotyped with distinct viral envelopes that influence vector tropism and transduction efficiency. Moreover, these vectors can be used to reprogram cells and generate induced pluripotent stem cells. This review aims to show the patents that resulted in improved safety and efficacy of lentiviral vector with important implications for clinical trials.
Center for Cell Therapy and Regional Blood Center; National Institute of Science and Technology in Stem Cell Therapy; Ribeirao Preto, Brazil. virginia.picanco.castro@gmail.com
Virginia
V
Picanco-Castro
Elisa Maria
EM
de Sousa Russo-Carbolante
Dimas
D
Tadeu Covas
D000818:Animals; D002460:Cell Line; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors; D015497:HIV-1 / Q000235:genetics; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000378:metabolism; D016086:Lentivirus / Q000235:genetics*; D051379:Mice; D010330:Patents as Topic; D019076:Transgenes / Q000235:genetics